XML 48 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration and License Agreement - Additional Information (Details) - Bristol-Myers Squibb Company - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2020
May 31, 2020
Jun. 30, 2021
Jun. 30, 2021
Aug. 12, 2021
Jul. 31, 2021
Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Non-refundable upfront payment received     $ 50,000,000 $ 50,000,000      
Collaboration and License Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Collaboration term expiration period   42 months          
Initial nonrefundable upfront fee received $ 50,000,000.0            
Non-refundable upfront payment received   $ 50,000,000.0          
Deferred revenue recognized     300,000 400,000      
Deferred revenue     49,500,000 49,500,000     $ 49,900,000
Deferred revenue, current     8,800,000 8,800,000     2,100,000
Deferred revenue, noncurrent     $ 40,700,000 $ 40,700,000     $ 47,800,000
Collaboration and License Agreement | Subsequent Events | Reclassification Adjustment              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Deferred revenue, current         $ 6,200,000 $ 6,200,000  
Deferred revenue, noncurrent         $ (6,200,000) $ (6,200,000)  
Collaboration and License Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Milestone payments entitled to be received   301,000,000.0          
Collaboration and License Agreement | Maximum | Research, Development and Regulatory Milestones              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Milestone payments entitled to be received   176,000,000.0          
Collaboration and License Agreement | Maximum | Commercial Milestones              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Milestone payments entitled to be received   $ 125,000,000.0